Prolonged endocrine therapy in the management of hormone receptor-positive early-stage breast cancer: What is the appropriate duration?
In their study, they discussed the clinical benefits associated with 5 years of endocrine therapy in the treatment of hormone receptor-positive (a hormone-receptor-positive tumor is a tumor which has cells that express receptors for certain hormones), early-stage breast cancer (ESBC). The authors reviewed the study findings from several randomized controlled trials and meta-analyses, which incorporated clinical outcomes from pre-and postmenopausal, hormone receptor-positive, ESBC patients. They found that hormone receptor-positive, ESBC patients treated with 5 years of endocrine therapy, who are node-negative (the cancer has not spread to the lymph nodes) with tumors <2 cm, will unlikely benefit from five additional years of treatment. Conversely, in women with larger tumors and node-positive disease, 7–8 total years of endocrine therapy may be indicated. Ultimately, clinicians should also consider the attendant side effects from endocrine therapy, namely bone fractures, cardiovascular symptoms, and vasomotor symptoms, when considering the appropriate treatment regimen.
You can read the full article at The Journal of Obstetrics and Gyneacology Research
For a full inventory of articles published by Womens Cancer Research Foundation please visit our Publications Page
About Women’s Cancer Research Foundation:
The Women’s Cancer Research Foundation (WCRF) is one of the most active research organizations in the nation. We are dedicated to studying and evaluating novel treatments for women afflicted with breast, ovarian, endometrial, and cervical cancers. The WCRF persistently endeavors to make a difference in women’s lives by offering them hope, strength, and progress.
Laguna Beach, CA 92651
PH: (949) 642-5165
Follow Us On Social Media:
Comments